QCLS

Q/C Technologies Inc

0.4350

Oct 30 • 3:59 PM ET -0.0054 (-1.23%)

0.4251

Aftermarket • 7:48 PM ET -0.0099 (-2.28%)

Technology Computer Hardware USA Nano NASD

Peers: QUBT XNDU IONQ QBTS POET GSIT ALMU MOBX INFQ LWLG

| Held by: VXF

Scroll to Statements

Index	-
Market Cap	3.56M
Enterprise Value	-3.93M
Income	-18.34M
Sales	0.00M
Book/sh	1.95
Cash/sh	1.34
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	2
IPO	Jul 24, 2008

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.22
P/C	0.32
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	3.29
Current Ratio	3.29
Debt/Eq	0.02
LT Debt/Eq	0.01
Option/Short	No / Yes

EPS (ttm)	-4.34
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	80.53% 77.48%
Sales past 3/5Y	- -
EPS Y/Y TTM	98.32%
Sales Y/Y TTM	-
EPS Q/Q	95.50%
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	-79.41% -14.63%

Insider Own	4.25%
Insider Trans	0.51%
Inst Own	9.00%
Inst Trans	1.99%
ROA	-82.79%
ROE	-108.00%
ROIC	-85.83%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-19.40%
SMA50	-60.11%
SMA200	-85.85%
Trades

Shs Outstand	8.19M
Shs Float	7.84M
Short Float	12.72%
Short Ratio	0.20
Short Interest	1.00M
52W High	8.17 -94.68%
52W Low	0.42 3.55%
Volatility	10.70% 9.93%
ATR (14)	0.09
RSI (14)	27.40
Beta	2.17
Rel Volume	0.07
Avg Volume	4.89M
Volume	318,279

Perf Week	-8.03%
Perf Month	-43.89%
Perf Quarter	-84.18%
Perf Half Y	-88.34%
Perf YTD	-89.10%
Perf Year	-87.13%
Perf 3Y	-99.97%
Perf 5Y	-100.00%
Perf 10Y	-100.00%
Recom	1.00
Target Price	32.00
Prev Close	0.44
Price	0.44
Change %	-1.23%

Oct-01-26 02:43PM	Q/C Technologies Announces Research Collaboration with Sandia National Laboratories, a $5 Billion U.S. Department of Energy Lab (GlobeNewswire) -8.91%
Sep-30-26 08:45AM	Q/C Technologies Announces Research Collaboration with Sandia National Laboratories, a $5 Billion U.S. Department of Energy Lab (GlobeNewswire)
Sep-15-26 09:00AM	Q/C Technologies Names Yossef Ehrlichman Chief Technology Officer to Lead Optical Processor Development (GlobeNewswire) -21.21%
Aug-04-26 09:15AM	Q/C Technologies Appoints Veteran Silicon Photonics Engineer Yossef Ehrlichman as Founding Manager, Photonic Integrated Circuit (PIC) Development (GlobeNewswire) +6.55%
Jul-01-26 09:44AM	Q/C Technologies Relocates Headquarters to San Francisco in Proximity to World-Class Engineering Experts for Photonic Computing and Optical AI Inference Initiative (GlobeNewswire)
09:15AM	Loading…
Jun-30-26 09:15AM	Q/C Technologies Relocates Headquarters to San Francisco in Proximity to World-Class Engineering Experts for Photonic Computing and Optical AI Inference Initiative (GlobeNewswire) +5.41%
Mar-18-26 09:15AM	Q/C Technologies Launches Optical Processing Unit (OPU) Initiative to Develop Proprietary Silicon Photonic Computing Architecture for AI Inference (GlobeNewswire)
Jan-20-26 09:15AM	Q/C Technologies Appoints AI Systems Leader Chelsea Voss to Board of Directors (GlobeNewswire)
Dec-09-25 09:15AM	Quantum-Class Computing Developer Q/C Technologies Welcomes Strategic Advisor Martin Shkreli (GlobeNewswire)
Oct-30-25 09:15AM	Q/C Technologies Introduces Proprietary qc-LPU100 Brand of Quantum-Class Laser Processing Units (GlobeNewswire) -11.05%
Oct-16-25 09:15AM	Q/C Technologies Appoints Technion Professor Dr. Steven Frankel as Senior Quantum Advisor to Advance Photonic and Quantum-Class Computing Initiatives (GlobeNewswire) +16.03%
Sep-25-25 09:15AM	Q/C Technologies (Formerly TNF Pharmaceuticals) Commences Trading on Nasdaq Under New Ticker Symbol "QCLS" (Business Wire) -9.62%
Sep-24-25 09:15AM	TNF Pharmaceuticals Announces Name Change to Q/C Technologies and New Ticker Symbol "QCLS" to Reflect Strategic Focus on Quantum Class Photonic Computing (Business Wire) +48.15%
Sep-17-25 09:24AM	TNF Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement (Business Wire)
Sep-08-25 09:15AM	TNF Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference (Business Wire) +14.24%
09:15AM	Loading…
Sep-04-25 09:15AM	TNF Pharmaceuticals Announces Closing of $7 Million Private Placement (Business Wire)
Sep-02-25 09:20AM	PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications (Business Wire) -21.33%
09:15AM	TNF Pharmaceuticals Secures Exclusive Global Rights to Innovative Light Speed Computing Accelerator for Use in Cryptocurrency Applications (Business Wire)
Aug-29-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) -21.59%
Aug-28-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) -31.56%
09:15AM	TNF Pharmaceuticals Announces Reverse Stock Split For Nasdaq Listing Compliance (Business Wire)
Aug-27-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +15.53%
Aug-26-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +13.72%
Aug-25-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +9.60%
Aug-22-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) -16.78%
Aug-21-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) -20.86%
Aug-20-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
Aug-19-25 05:20PM	TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation (Business Wire) -6.97%
Aug-18-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
Aug-13-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
10:30AM	Loading…
Aug-12-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
Aug-11-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +13.53%
Aug-07-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) -5.84%
Aug-04-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +5.74%
Jul-31-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) -12.72%
Jul-30-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) -19.04%
Jul-29-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +23.52%
Jul-24-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +17.75%
Jul-21-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +47.89%
Jul-16-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
Jun-24-25 09:15AM	TNF Pharmaceuticals Collaborates with DADA2 Foundation for Compassionate Use Study of Isomyosamine in Rare Pediatric Autoinflammatory Disease (Business Wire)
May-08-25 09:20AM	TNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating TNF-Driven Inflammation in Patients Receiving GLP-1 Agonists (Business Wire)
Apr-22-25 09:15AM	TNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug Development (Business Wire)
Apr-16-25 09:15AM	TNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at British Geriatrics Society's Spring Meeting 2025 (Business Wire) -9.00%
Mar-18-25 09:25AM	TNF Pharmaceuticals presents isomyosamine data (TipRanks)
Mar-17-25 09:15AM	TNF Pharmaceuticals Delivers Podium Presentation of Novel Oral TNF-Alpha Inhibitor at Premier International Conference on Frailty and Sarcopenia (Business Wire) +5.49%
Mar-05-25 09:00AM	TNF Pharmaceuticals to Host Investor Conference Call and Webcast Featuring Clinical Scientific Updates on Thursday, March 6, 2025 (Business Wire)
Feb-25-25 09:20AM	TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor (Business Wire) +5.55%
Jan-29-25 09:15AM	TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment (Business Wire) -9.83%
Jan-15-25 09:15AM	TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion (Business Wire) -20.27%
Dec-19-24 09:15AM	TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs (Business Wire)
Dec-09-24 09:00AM	TNF Pharmaceuticals Presents Statistically Significant Phase 2a Trial Results for Novel Sarcopenia/Frailty Treatment at Prestigious International Conference (Business Wire) +13.71%
Oct-02-24 09:10AM	TNF Pharmaceuticals Announces Strategic Equity Investment Priced at a Premium to Market (Business Wire) +18.62%
Aug-21-24 09:00AM	TNF Pharmaceuticals Prepares to Advance Lead Clinical Program Targeting Age-Related Decline (Business Wire) -11.39%
Jul-24-24 09:05AM	TNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol TNFA Effective Before Market Open Today (Business Wire) +9.89%
Jul-22-24 09:00AM	MyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc. (Business Wire)
Jul-15-24 07:52AM	MYMD Stock Earnings: MyMD Pharmaceuticals Reported Results for Q1 2024 (InvestorPlace)
Jun-17-24 09:00AM	MyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical Officer (Business Wire)
May-21-24 09:00AM	PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease (Business Wire) -12.18%
09:00AM	MyMD Pharmaceuticals Secures Strategic Investments (Business Wire)
May-17-24 03:52PM	MYMD Stock Earnings: MyMD Pharmaceuticals Reported Results for Q4 2023 (InvestorPlace) +7.31%
Apr-09-24 08:21AM	Why Is MyMD Pharmaceuticals (MYMD) Stock Up 35% Today? (InvestorPlace)
Mar-05-24 09:15AM	MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing (Business Wire)
Feb-13-24 11:45AM	MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing (Business Wire) -14.49%
Dec-29-23 12:45PM	MyMD Pharmaceuticals Releases Positive Clinical Trial Results For Sarcopenia Treatment Drug (ACCESSWIRE)
Dec-06-23 09:15AM	MyMD Pharmaceuticals Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis (Business Wire) -5.75%
Oct-19-23 09:00AM	MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD, Reduced Acute Inflammatory Pain (Business Wire)
Oct-04-23 07:30AM	MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF- Market Disrupter, at BioFuture 2023 (Business Wire)
Aug-14-23 08:30AM	FDA Accepts MyMD Pharmaceuticals Investigational New Drug Application (IND) for Phase 2 Study of oral TNF- inhibitor MYMD-1® in Rheumatoid Arthritis (RA) (Business Wire) -7.64%
Aug-02-23 08:30AM	MyMD Pharmaceuticals to Hold Conference Call Today to Discuss Phase 2 Trial Results (Business Wire)
Jul-31-23 09:00AM	MyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF- Inhibitor MYMD-1® in Sarcopenia/Age-Related Frailty (Business Wire) +31.82%
Apr-12-23 08:30AM	MyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan (Business Wire) -8.54%
Mar-20-23 08:55AM	MyMD Pharmaceuticals® and Charles River Present Positive Data for Next Generation, Oral TNF- Inhibitor MYMD-1® in Rheumatoid Arthritis (Business Wire) -5.00%
Mar-08-23 08:30AM	MyMD Joins LOT Network in Effort to Protect Company and Shareholders from Patent Trolls (Business Wire)
Mar-02-23 08:30AM	MyMD Announces U.S. Drug Enforcement Administration (DEA) Determines Supera-CBD is not a Controlled Substance or Listed Chemical (Business Wire) +5.62%
Feb-28-23 08:30AM	MyMD Pharmaceuticals® Announces Upcoming Presentation of Preclinical Rheumatoid Arthritis Data for Oral TNF- Inhibitor MYMD-1® at the Society of Toxicology 2023 Annual Meeting (Business Wire)
Feb-21-23 08:45AM	MyMD Announces $15 Million Offering with Existing Investors (Business Wire) -7.32%
Dec-06-22 09:40AM	ADDING MULTIMEDIA MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022 (Business Wire) -9.74%
Nov-17-22 08:00AM	MyMD Pharmaceuticals® Announces Upcoming Presentation of Late-Breaking Data for MYMD-1® at the 2022 British Society for Immunology (BSI) Congress (Business Wire)
Nov-14-22 08:00AM	MyMD Pharmaceuticals Announces Publication of Phase 1 Data for oral TNF-alpha Inhibitor MYMD-1® in Peer-Reviewed Journal Drug Research (Business Wire) -5.96%
Sep-20-22 08:00AM	MyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan (Business Wire) -6.25%
Aug-30-22 08:30AM	MyMD Pharmaceuticals Receives Grant From European Patent Office for Supera-CBD Compound (Business Wire) -7.27%
Aug-03-22 09:45AM	Data Showing MyMD Pharmaceuticals MYMD-1® May Extend Life and Improve Health Published in the Journal of Gerontology: Biological Sciences (Business Wire)
Jul-29-22 09:19AM	Is MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) Popular Amongst Insiders? (Simply Wall St.) +5.79%
Jul-26-22 07:30AM	MyMD Pharmaceuticals® Advances Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan (Business Wire) -11.44%
Jul-12-22 09:30AM	MyMD Pharmaceuticals to Collaborate with Bascom Palmer Eye Institute to Study MYMD-1 in Ophthalmic Conditions (Business Wire) +17.10%
Jun-21-22 10:30AM	MyMD Pharmaceuticals Advances Phase 2 Multi-Center Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan (Business Wire)
Apr-05-22 09:15AM	MyMD Pharmaceuticals Accelerates Pace of New Patient Dosing in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan (Business Wire) -8.79%
Mar-24-22 09:26AM	MyMD Pharmaceuticals Announces Live Appearance on Cheddar News Network Today March 24 (Business Wire)
Feb-23-22 09:15AM	MyMD Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan (Business Wire) -9.49%
Feb-20-22 08:37AM	We're Keeping An Eye On MyMD Pharmaceuticals' (NASDAQ:MYMD) Cash Burn Rate (Simply Wall St.)
Feb-08-22 09:15AM	MyMD Pharmaceuticals Announces Positive Clinical Data in Advance of Upcoming Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan (Business Wire) -5.13%
Feb-07-22 08:38PM	NorthRock Partners, LLC Buys PepsiCo Inc, iShares MSCI EAFE ETF, iShares MSCI Emerging Markets ... (GuruFocus.com)
Jan-05-22 09:15AM	MyMD Pharmaceuticals Announces Issuance of New U.S. Patent Covering MYMD-1 in a Method of Treating Sarcopenia (Business Wire) -5.26%
Dec-29-21 09:15AM	MyMD Pharmaceuticals Investment Company Oravax Medical Signs Cooperation and Purchase Agreement for Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccine to be Commercialized in Southeast Asia (Business Wire)
Dec-16-21 10:50AM	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating MyMD Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors (PR Newswire)
Dec-01-21 10:05AM	MyMD Pharmaceuticals to Participate in Two Investor Conferences During December 2021 (Business Wire)
Nov-23-21 09:25AM	MyMD Pharmaceuticals Announces Issuance of U.S. Patent Covering Lead Drug Candidate MYMD-1 in a Method of Extending Lifespan (Business Wire)
Nov-18-21 09:15AM	MyMD Pharmaceuticals Investment Company Oravax Medical and Genomma Lab Announce Joint Venture to Develop and Commercialize Oral COVID-19 Vaccine in Mexico and Drive Business Development in Latin America (Business Wire) -9.76%
Nov-16-21 09:25AM	MyMD Pharmaceuticals Receives FDA IND Clearance to Begin Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan (Business Wire) -11.75%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Voss Chelsea Sierra	Director	Mar 30 '26	Buy	3.15	1,753	5,522	61,555	May 14 05:33 PM

Q/C Technologies, Inc. engages in the provision of energy-efficient blockchain and cryptocurrency infrastructure through quantum-class laser-based computing. It operates through the Pharmaceuticals and Computing Technology segments. The Pharmaceuticals segment operates in the clinical-stage pharmaceutical space and is specifically focused on isomyosamine (formerly MYMD-1). The Computing Technology segment is involved in the development and eventual application of quantum computing technology, both for cryptocurrency applications and beyond. The company was founded in 1989 and is headquartered in New York, NY.

Executive Chairman of the BoardMr. Joshua N. Silverman

Chief Financial OfficerMr. Ian Thomas Rhodes CPA

Chief Medical Officer & DirectorDr. Mitchell Glass M.D.

Chief Technology OfficerMr. Yossef Ehrlichman

Investor Relations OfficerRobert Schatz

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

QCLS

Q/C Technologies Inc

Upgrade your Finviz experience